CL2013001557A1 - Composicion farmaceutica que comprende granulos con a) un compuesto derivado de imidazo[4,5-c]quinolina, b) por lo menos un tensoactivo no ionico que es la vitamina e tpgs y c) por lo menos un agente mejorador de disolucion; proceso de elaboracion; kit; y uso para tratar una enfermedad proliferativa o dependiente de la cinasa mtor. - Google Patents
Composicion farmaceutica que comprende granulos con a) un compuesto derivado de imidazo[4,5-c]quinolina, b) por lo menos un tensoactivo no ionico que es la vitamina e tpgs y c) por lo menos un agente mejorador de disolucion; proceso de elaboracion; kit; y uso para tratar una enfermedad proliferativa o dependiente de la cinasa mtor.Info
- Publication number
- CL2013001557A1 CL2013001557A1 CL2013001557A CL2013001557A CL2013001557A1 CL 2013001557 A1 CL2013001557 A1 CL 2013001557A1 CL 2013001557 A CL2013001557 A CL 2013001557A CL 2013001557 A CL2013001557 A CL 2013001557A CL 2013001557 A1 CL2013001557 A1 CL 2013001557A1
- Authority
- CL
- Chile
- Prior art keywords
- tpgs
- imidazo
- proliferative
- quinoline
- vitamin
- Prior art date
Links
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 1
- 101150097381 Mtor gene Proteins 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical group OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004090 dissolution Methods 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000008187 granular material Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000002736 nonionic surfactant Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41953810P | 2010-12-03 | 2010-12-03 | |
| US201161436324P | 2011-01-26 | 2011-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001557A1 true CL2013001557A1 (es) | 2013-10-25 |
Family
ID=45346568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001557A CL2013001557A1 (es) | 2010-12-03 | 2013-05-31 | Composicion farmaceutica que comprende granulos con a) un compuesto derivado de imidazo[4,5-c]quinolina, b) por lo menos un tensoactivo no ionico que es la vitamina e tpgs y c) por lo menos un agente mejorador de disolucion; proceso de elaboracion; kit; y uso para tratar una enfermedad proliferativa o dependiente de la cinasa mtor. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130245061A1 (es) |
| EP (1) | EP2645999A2 (es) |
| JP (1) | JP2013544845A (es) |
| KR (1) | KR20140010009A (es) |
| CN (1) | CN103237544A (es) |
| AR (1) | AR084067A1 (es) |
| AU (1) | AU2011336478A1 (es) |
| CA (1) | CA2817618A1 (es) |
| CL (1) | CL2013001557A1 (es) |
| CO (1) | CO6801722A2 (es) |
| EC (1) | ECSP13012654A (es) |
| GT (1) | GT201300144A (es) |
| MA (1) | MA34806B1 (es) |
| MX (1) | MX2013006187A (es) |
| NZ (1) | NZ610467A (es) |
| PE (1) | PE20140792A1 (es) |
| PH (1) | PH12013501098A1 (es) |
| RU (1) | RU2013130224A (es) |
| SG (1) | SG190210A1 (es) |
| TW (1) | TW201304779A (es) |
| WO (1) | WO2012075253A2 (es) |
| ZA (1) | ZA201303223B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013192367A1 (en) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2014048782A1 (en) * | 2012-09-27 | 2014-04-03 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
| RU2743343C2 (ru) | 2015-04-02 | 2021-02-17 | Мерк Патент Гмбх | Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм |
| AU2016263176A1 (en) | 2015-05-20 | 2017-12-07 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| US20210346374A1 (en) * | 2016-10-03 | 2021-11-11 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 receptor antagonist |
| CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| ES3022232T3 (en) * | 2019-08-07 | 2025-05-28 | Aclipse One Inc | Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
| PL4076404T3 (pl) * | 2019-12-20 | 2024-02-19 | Intervet International B.V. | Kompozycja farmaceutyczna pirazolu |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| AU2004295061B2 (en) * | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007137040A2 (en) * | 2006-05-16 | 2007-11-29 | Decode Genetics Ehf | 7-(acryloyl) indole compositions and methods for making and using same |
| PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| WO2008079629A2 (en) * | 2006-12-21 | 2008-07-03 | Boehringer Ingelheim International Gmbh | Formulations with improved bioavailability |
| CN101616672A (zh) | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
-
2011
- 2011-12-01 PE PE2013001327A patent/PE20140792A1/es not_active Application Discontinuation
- 2011-12-01 SG SG2013035480A patent/SG190210A1/en unknown
- 2011-12-01 RU RU2013130224/15A patent/RU2013130224A/ru not_active Application Discontinuation
- 2011-12-01 NZ NZ610467A patent/NZ610467A/en not_active IP Right Cessation
- 2011-12-01 AR ARP110104478A patent/AR084067A1/es unknown
- 2011-12-01 PH PH1/2013/501098A patent/PH12013501098A1/en unknown
- 2011-12-01 KR KR1020137017289A patent/KR20140010009A/ko not_active Withdrawn
- 2011-12-01 CN CN2011800576307A patent/CN103237544A/zh active Pending
- 2011-12-01 MA MA35945A patent/MA34806B1/fr unknown
- 2011-12-01 MX MX2013006187A patent/MX2013006187A/es not_active Application Discontinuation
- 2011-12-01 US US13/989,250 patent/US20130245061A1/en not_active Abandoned
- 2011-12-01 CA CA2817618A patent/CA2817618A1/en not_active Abandoned
- 2011-12-01 AU AU2011336478A patent/AU2011336478A1/en not_active Abandoned
- 2011-12-01 JP JP2013542171A patent/JP2013544845A/ja active Pending
- 2011-12-01 EP EP11794907.3A patent/EP2645999A2/en not_active Withdrawn
- 2011-12-01 WO PCT/US2011/062837 patent/WO2012075253A2/en not_active Ceased
- 2011-12-02 TW TW100144445A patent/TW201304779A/zh unknown
-
2013
- 2013-05-03 ZA ZA2013/03223A patent/ZA201303223B/en unknown
- 2013-05-30 CO CO13133022A patent/CO6801722A2/es not_active Application Discontinuation
- 2013-05-31 CL CL2013001557A patent/CL2013001557A1/es unknown
- 2013-06-03 EC ECSP13012654 patent/ECSP13012654A/es unknown
- 2013-06-03 GT GT201300144A patent/GT201300144A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2645999A2 (en) | 2013-10-09 |
| ECSP13012654A (es) | 2013-08-30 |
| JP2013544845A (ja) | 2013-12-19 |
| TW201304779A (zh) | 2013-02-01 |
| SG190210A1 (en) | 2013-06-28 |
| CO6801722A2 (es) | 2013-11-29 |
| AR084067A1 (es) | 2013-04-17 |
| AU2011336478A1 (en) | 2013-06-06 |
| MA34806B1 (fr) | 2014-01-02 |
| MX2013006187A (es) | 2013-07-15 |
| ZA201303223B (en) | 2014-01-29 |
| NZ610467A (en) | 2015-01-30 |
| PH12013501098A1 (en) | 2013-07-08 |
| WO2012075253A3 (en) | 2012-08-09 |
| GT201300144A (es) | 2014-06-09 |
| KR20140010009A (ko) | 2014-01-23 |
| CA2817618A1 (en) | 2012-06-07 |
| RU2013130224A (ru) | 2015-01-10 |
| CN103237544A (zh) | 2013-08-07 |
| WO2012075253A2 (en) | 2012-06-07 |
| PE20140792A1 (es) | 2014-07-09 |
| US20130245061A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001557A1 (es) | Composicion farmaceutica que comprende granulos con a) un compuesto derivado de imidazo[4,5-c]quinolina, b) por lo menos un tensoactivo no ionico que es la vitamina e tpgs y c) por lo menos un agente mejorador de disolucion; proceso de elaboracion; kit; y uso para tratar una enfermedad proliferativa o dependiente de la cinasa mtor. | |
| CL2013001120A1 (es) | Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune. | |
| CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
| CL2013002033A1 (es) | Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| MX386413B (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| ES2526606T3 (es) | Composición farmacéutica sólida que comprende amlodipina y losartán | |
| BR112013013435A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto. | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| CL2015000499A1 (es) | Uso de un agente farmacéuticamente aceptable que elimina el antígeno de superficie de la hepatitis b de la sangre y un segundo agente que estimula la función inmunitaria, para tratar hepatitis b o coinfección hepatitis b/hepatitis d; y composición que comprende ambos agentes. | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| CL2014000601A1 (es) | Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal. | |
| BR112014033055A8 (pt) | Inibidores seletivos de delta pi3k | |
| BRPI0618845A2 (pt) | composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero | |
| CL2014003171A1 (es) | Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica. | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. | |
| CL2013002003A1 (es) | Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc | |
| CL2015001342A1 (es) | Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer. |